Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics ...
Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics ...
Source: pr-inside.com
Page 3 - Gina Cestari News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Gina Cestari. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Gina Cestari Today - Breaking & Trending Today
Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones
CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate Encouraging endometrial and breast cancer data in ongoing ONA-XR Phase 2 trials, with additional data updates expected in... | January 4, 2023
Source: marketscreener.com
Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer
Data presented at San Antonio Breast Cancer Symposium® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer PFS follows... | December 8, 2022
Source: marketscreener.com
Context Therapeutics® Announces Clinical Updates on ONA-XR
Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented...
Source: globenewswire.com
ThinkEquity LLC: Context Therapeutics to Participate in the ThinkEquity Conference
Philadelphia, Pennsylvania--(Newsfile Corp. - October 20, 2022) - Context Therapeutics Inc. (NASDAQ: CNTX) ("Context" or the "Company"), a women's oncology company developing novel treatments for breast
Source: finanznachrichten.de